APA (7th ed.) Citation

Shim, J., Choi, S., Yoon, S., Choi, R. J., Park, J., Lee, E. H., . . . Kang, S. (2022). Etomoxir, a carnitine palmitoyltransferase 1 inhibitor, combined with temozolomide reduces stemness and invasiveness in patient-derived glioblastoma tumorspheres. Cancer Cell International, 22(1), 1. https://doi.org/10.1186/s12935-022-02731-7

Chicago Style (17th ed.) Citation

Shim, Jin-Kyoung, et al. "Etomoxir, a Carnitine Palmitoyltransferase 1 Inhibitor, Combined with Temozolomide Reduces Stemness and Invasiveness in Patient-derived Glioblastoma Tumorspheres." Cancer Cell International 22, no. 1 (2022): 1. https://doi.org/10.1186/s12935-022-02731-7.

MLA (9th ed.) Citation

Shim, Jin-Kyoung, et al. "Etomoxir, a Carnitine Palmitoyltransferase 1 Inhibitor, Combined with Temozolomide Reduces Stemness and Invasiveness in Patient-derived Glioblastoma Tumorspheres." Cancer Cell International, vol. 22, no. 1, 2022, p. 1, https://doi.org/10.1186/s12935-022-02731-7.